glp 1 select trial Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design GLP-1 Antagonists Increase Plan Drug

Specifically, it stimulates the release of neurotransmitters like norepinephrine and dopamine, known to reduce hunger and increase feelings of fullness

For most licensed weight loss medicines, menstrual changes are not a direct pharmacological effect of the drug itself, but rather a secondary consequence of significant or rapid weight loss and the associated changes in energy availability and body composition

& Cohen, P

That label also specifies the 25 mg tablet dosing pathway

The FDA has received adverse-event reports involving compounded semaglutide and tirzepatide, including dosing errors and events requiring medical attention